Encompass Health (US:EHC)2025-05-01 19:25Financial Performance - Net operating revenues for Q1 2025 were $1,455.4 million, a 10.6% increase from $1,316.0 million in Q1 2024[15] - Income from continuing operations for Q1 2025 was $197.0 million, up 40.5% from $140.1 million in Q1 2024[15] - Earnings per share attributable to Encompass Health for continuing operations increased to $1.50 in Q1 2025 from $1.13 in Q1 2024, representing a 32.8% growth[15] - Adjusted EBITDA for the same period rose to $313.6 million, compared to $273.0 million in 2024, reflecting an increase of about 14.9%[62] - Net income for Q1 2025 was $196.5 million, up 41.6% from $138.8 million in Q1 2024[130] - The increase in net income attributable to Encompass Health was 34.7%, reaching $151.5 million compared to $112.5 million in 2024[82] Assets and Liabilities - Total assets as of March 31, 2025, were $6,641.3 million, compared to $6,534.7 million as of December 31, 2024, reflecting a 1.6% increase[17] - Total current liabilities as of March 31, 2025, were $856.0 million, compared to $841.0 million as of December 31, 2024[17] - Long-term debt, net of current portion, decreased to $2,333.2 million as of March 31, 2025, from $2,359.2 million at the end of 2024, a reduction of 1.1%[42] - Total current assets increased to $647.4 million as of March 31, 2025, compared to $609.5 million as of December 31, 2024[121] Cash Flow and Investments - Cash and cash equivalents at the end of Q1 2025 were $95.8 million, up from $85.4 million at the end of Q4 2024[17] - Net cash provided by operating activities for Q1 2025 was $288.6 million, an increase from $238.8 million in Q1 2024[22] - The company reported an increase in net cash used in investing activities to $(158.5) million for the three months ended March 31, 2025, compared to $(129.7) million in 2024, primarily due to increased purchases of property and equipment[110] - The company expects to fund future capital expenditures using cash on hand and borrowings under its $1 billion revolving credit facility[113] Shareholder Returns - Dividends declared in Q1 2025 were $0.17 per share, totaling $17.4 million[19] - The company repurchased $32.1 million of common stock in Q1 2025[22] - The total number of shares repurchased during Q1 2025 was 532,957 at an average price of $95.55 per share[140] - The maximum number of shares that may yet be purchased under the repurchase plan is approximately $458.1 million[140] Operational Metrics - The company operated 167 inpatient rehabilitation hospitals as of March 31, 2025, with a majority being wholly owned[28] - The number of discharges increased by 6.3% to 64,985, while net patient revenue per discharge rose to $21,816, a 3.9% increase[84] - Occupancy percentage improved to 78.8%, up from 76.7% in the previous year, with occupied beds increasing by 6.3% to 8,793[84] - The company operates one reportable segment: inpatient rehabilitation, focusing on specialized rehabilitative treatment for various conditions[60] Regulatory and Market Environment - The company continues to face challenges related to regulatory compliance and staffing shortages, which may impact operational efficiency and costs[80] - The company remains optimistic about long-term demand for its services due to demographic trends, particularly the aging population[71] - Medicare accounted for 67.0% of consolidated net operating revenues for the three months ended March 31, 2025, up from 64.9% in 2024[81] - The 2026 Proposed Rule from CMS is expected to result in a net increase of approximately 2.7% in Medicare payment rates effective October 1, 2025[76] Future Outlook - The company plans to open new hospitals in Florida, Texas, and other states, adding a total of approximately 60 new beds in 2025[70] - The company has minimum amounts due under service contracts totaling $50.5 million for the remainder of 2025, with further commitments extending into subsequent years[58] - The company is currently evaluating the impact of new accounting standards on its financial statements, including ASU 2023-09, effective January 1, 2025[34]